Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Diabetes Reports
Erschienen in: Current Diabetes Reports 12/2021

01.12.2021 | Health Care Delivery Systems and Implementation in Diabetes (ME McDonnell and AR Sadhu, Section Editor)

Patient-Centered Diabetes Care of Cancer Patients

verfasst von: Anupam Kotwal, Yee-Ming M. Cheung, Grace Cromwell, Andjela Drincic, Houry Leblebjian, Zoe Quandt, Robert J. Rushakoff, Marie E. McDonnell

Erschienen in: Current Diabetes Reports | Ausgabe 12/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

There is a bidirectional relationship between cancer and diabetes, with one condition influencing the prognosis of the other. Multiple cancer therapies cause diabetes including well-established medications such as glucocorticoids and novel cancer therapies such as immune checkpoint inhibitors (CPIs) and phosphoinositide 3-kinase (PI3K) inhibitors.

Recent Findings

The nature and severity of diabetes caused by each therapy differ, with some predominantly mediated by insulin resistance, such as PI3K inhibitors and glucocorticoids, while others by insulin deficiency, such as CPIs. Studies have demonstrated diabetes from CPIs to be more rapidly progressing than conventional type 1 diabetes. There remains a scarcity of published guidance for the screening, diagnosis, and management of hyperglycemia and diabetes from these therapies. The need for such guidance is critical because diabetes management in the cancer patient is complex, individualized, and requires inter-disciplinary care.

Summary

In the present narrative review, we synthesize and summarize the most relevant literature pertaining to diabetes and hyperglycemia in the setting of these cancer therapies and provide an updated patient-centered framework for their evaluation and management.
Literatur
1.
Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin. 2010;60(4):207–21.PubMedCrossRef
2.
3.
4.
Pearson-Stuttard J, Zhou B, Kontis V, Bentham J, Gunter MJ, Ezzati M. Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. Lancet Diabetes Endocrinol. 2018;6(6):e6–e15.PubMedPubMedCentralCrossRef
5.
Zeng L, Biernacka KM, Holly JM, Jarrett C, Morrison AA, Morgan A, et al. Hyperglycaemia confers resistance to chemotherapy on breast cancer cells: the role of fatty acid synthase. Endocr Relat Cancer. 2010;17(2):539–51.PubMedCrossRef
6.
•• Silvestris N, Argentiero A, Beretta GD, Di Bartolo P, Montagnani M, Danesi R, et al. Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper. Crit Rev Oncol Hematol. 2020;154:103066. A recent consensus recommendation from Italian group on managmement of metabolic adverse events from targeted cancer therapies.PubMedCrossRef
7.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.PubMedCrossRef
8.
9.
• Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020. J Natl Compr Cancer Netw. 2020;18(3):230–41. Guidelines from oncology group on the managment of toxicities from immunotherpies.CrossRef
10.
Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev. 2019;40(1):17–65.PubMedCrossRef
11.
• Quandt Z, Young A, Perdigoto AL, Herold KC, Anderson MS. Autoimmune endocrinopathies: an emerging complication of immune checkpoint inhibitors. Annu Rev Med. 2021;72:313–30. A narrative review of available litereature on endocrine adverse events from immunotherapies, providing guidance on diagnosis and management of hyperglycemia and diabetes from immunutherapies as well.PubMedCrossRef
12.
•• Wright JJ, Powers AC, Johnson DB. Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol. 2021. An excellent narrative review of available litereature on endocrine adverse events from immunotherapies, providing guidance on diagnosis and management of these.
13.
Biadgo B, Abebe M. Type 2 diabetes mellitus and its association with the risk of pancreatic carcinogenesis: a review. Korean J Gastroenterol. 2016;67(4):168–77.PubMedCrossRef
14.
Arcidiacono B, Iiritano S, Nocera A, Possidente K, Nevolo MT, Ventura V, et al. Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp Diabetes Res. 2012;2012:789174.PubMedPubMedCentralCrossRef
15.
Barone BB, Yeh H-C, Snyder CF, Peairs KS, Stein KB, Derr RL, et al. Postoperative mortality in cancer patients with preexisting diabetes. Systematic review and meta-analysis. 2010;33(4):931–9.
16.
17.
Hisanaga K, Uchino H, Kakisu N, Miyagi M, Yoshikawa F, Sato G, et al. Pre-existing diabetes limits survival rate after immune checkpoint inhibitor treatment for advanced lung cancer: a retrospective study in Japan. Diabetes Metab Syndr Obes. 2021;14:773–81.PubMedPubMedCentralCrossRef
18.
Shankar B, Zhang J, Naqash AR, Forde PM, Feliciano JL, Marrone KA, et al. Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non–small cell lung cancer. JAMA Oncol. 2020;6(12):1952–6.PubMedCrossRef
19.
Tsang VHM, McGrath RT, Clifton-Bligh RJ, Scolyer RA, Jakrot V, Guminski AD, et al. Checkpoint inhibitor–associated autoimmune diabetes is distinct from type 1 diabetes. J Clin Endocrinol Metab. 2019;104(11):5499–506.PubMedCrossRef
20.
Mehtälä J, Khanfir H, Bennett D, Ye Y, Korhonen P, Hoti F. Pioglitazone use and risk of bladder cancer: a systematic literature review and meta-analysis of observational studies. Diabetol Int. 2019;10(1):24–36.PubMedCrossRef
21.
Wu JW, Filion KB, Azoulay L, Doll MK, Suissa S. Effect of long-acting insulin analogs on the risk of cancer: a systematic review of observational studies. Diabetes Care. 2016;39(3):486–94.PubMedCrossRef
22.
Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdòttir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia. 2009;52(9):1745–54.PubMedCrossRef
23.
Heckman-Stoddard BM, DeCensi A, Sahasrabuddhe VV, Ford LG. Repurposing metformin for the prevention of cancer and cancer recurrence. Diabetologia. 2017;60(9):1639–47.PubMedPubMedCentralCrossRef
24.
Overbeek JA, Bakker M, van der Heijden A, van Herk-Sukel MPP, Herings RMC, Nijpels G. Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2018;34(5):e3004.PubMedCrossRef
25.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.PubMedPubMedCentralCrossRef
26.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.PubMedCrossRef
27.
Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA. 2019;322(12):1155–66.PubMedPubMedCentralCrossRef
28.
Davis GM, Galindo RJ, Migdal AL, Umpierrez GE. Diabetes technology in the inpatient setting for management of hyperglycemia. Endocrinol Metab Clin N Am. 2020;49(1):79–93.CrossRef
29.
Perez A, Jansen-Chaparro S, Saigi I, Bernal-Lopez MR, Miñambres I, Gomez-Huelgas R. Glucocorticoid-induced hyperglycemia. J Diabetes. 2014;6(1):9–20.PubMedCrossRef
30.
Association AD. 12. Older adults: standards of medical care in diabetes—2021Diabetes Care. 2021;44(Supplement 1):S168-S79.
31.
Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, Klibanski A, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014;99(11):4078–85.PubMedCrossRef
32.
Faje AT, Lawrence D, Flaherty K, Freedman C, Fadden R, Rubin K, et al. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer. 2018;124(18):3706–14.PubMedCrossRef
33.
Barroso-Sousa R, Ott PA, Hodi FS, Kaiser UB, Tolaney SM, Min L. Endocrine dysfunction induced by immune checkpoint inhibitors: practical recommendations for diagnosis and clinical management. Cancer. 2018;124(6):1111–21.PubMedCrossRef
34.
Kotwal A. Hypophysitis from immune checkpoint inhibitors: challenges in diagnosis and management. Curr Opin Endocrinol Diabetes Obes. 2021;28(4):427–34.PubMedCrossRef
35.
Delivanis DA, Gustafson MP, Bornschlegl S, Merten MM, Kottschade L, Withers S, et al. Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms. J Clin Endocrinol Metab. 2017;102(8):2770–80.PubMedPubMedCentralCrossRef
36.
Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014;21(2):371–81.PubMedPubMedCentralCrossRef
37.
Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol. 2017;28(3):583–9.PubMedCrossRef
38.
Iyer PC, Cabanillas ME, Waguespack SG, Hu MI, Thosani S, Lavis VR, et al. Immune-related thyroiditis with immune checkpoint inhibitors. Thyroid. 2018;28(10):1243–51.PubMedPubMedCentralCrossRef
39.
Kotwal A, Kottschade L, Ryder M. PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients. Thyroid. 2020;30(2):177–84.PubMedPubMedCentralCrossRef
40.
Hughes J, Vudattu N, Sznol M, Gettinger S, Kluger H, Lupsa B, et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care. 2015;38(4):e55–7.PubMedPubMedCentralCrossRef
41.
• Kotwal A, Haddox C, Block M, Kudva YC. Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes. BMJ Open Diabetes Res Care. 2019;7(1):e000591. A study analyzing Mayo Clinic cohort of cancer patients treated with immune checkpoint inhibitors demonstrated that they may not only cause new-onset insulin-dependent diabetes but can also worsen underlying prediabetes or type 2 diabetes.PubMedPubMedCentralCrossRef
42.
43.
Gaballa S, Hlaing KM, Mahler N, Moursy S, Ahmed A. A rare case of immune-mediated primary adrenal insufficiency with cytotoxic T-lymphocyte antigen-4 inhibitor ipilimumab in metastatic melanoma of lung and neck of unknown primary. Cureus. 2020;12(6):e8602.PubMedPubMedCentral
44.
Abdallah D, Johnson J, Goldner W, Addasi N, Desouza C, Kotwal A. Adrenal insufficiency from immune checkpoint inhibitors masquerading as sepsis. JCO Oncol Pract. 2021;17(4):212–4.PubMedCrossRef
45.
Gnanendran SS, Miller JA, Archer CA, Jain SV, Hwang SJE, Peters G, et al. Acquired lipodystrophy associated with immune checkpoint inhibitors. Melanoma Res. 2020;30(6):599–602.PubMedCrossRef
46.
Piranavan P, Li Y, Brown E, Kemp EH, Trivedi N. Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies. J Clin Endocrinol Metab. 2018:jc.2018-01151-jc.2018.
47.
El Kawkgi OM, Li D, Kotwal A, Wermers RA. Hypoparathyroidism: an uncommon complication associated with immune checkpoint inhibitor therapy. Mayo Clin Proc Innov Qual Outcomes. 2020;4(6):821–5.PubMedPubMedCentralCrossRef
48.
• Mourad D, Azar NS, Eid AA, Azar ST. Immune checkpoint inhibitor-induced diabetes mellitus: potential role of T cells in the underlying mechanism. Int J Mol Sci. 2021;22(4). A narrative review providig insights into the still unclear mechanism behind immune checkpoint inhibitor-induced diabetes.
49.
Krokowski M, Abel M, Teodorczyk A, Szadkowska A, Pyrżak B, Rymkiewicz-Kluczyńska B, et al. Type 1 diabetes and prediabetic state in a monozygotic triplet. Acta geneticae medicae et gemellologiae: twin research. 1998;47(3-4):171–6.PubMedCrossRef
50.
Haseda F, Imagawa A, Murase-Mishiba Y, Sano H, Hirano-Kuwata S, Ueda H, et al. Low CTLA-4 expression in CD4+ helper T-cells in patients with fulminant type 1 diabetes. Immunol Lett. 2011;139(1-2):80–6.PubMedCrossRef
51.
Nielsen C, Hansen D, Husby S, Jacobsen BB, Lillevang ST. Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. Tissue Antigens. 2003;62(6):492–7.PubMedCrossRef
52.
Perri V, Russo B, Crinò A, Schiaffini R, Giorda E, Cappa M, et al. Expression of PD-1 molecule on regulatory T lymphocytes in patients with insulin-dependent diabetes mellitus. Int J Mol Sci. 2015;16(9):22584–605.PubMedPubMedCentralCrossRef
53.
Fujisawa R, Haseda F, Tsutsumi C, Hiromine Y, Noso S, Kawabata Y, et al. Low programmed cell death-1 (PD-1) expression in peripheral CD4(+) T cells in Japanese patients with autoimmune type 1 diabetes. Clin Exp Immunol. 2015;180(3):452–7.PubMedPubMedCentralCrossRef
54.
Yoneda S, Imagawa A, Hosokawa Y, Baden MY, Kimura T, Uno S, et al. T-lymphocyte infiltration to islets in the pancreas of a patient who developed type 1 diabetes after administration of immune checkpoint inhibitors. Diabetes Care. 2019;42(7):e116–e8.PubMedCrossRef
55.
Lo Preiato V, Salvagni S, Ricci C, Ardizzoni A, Pagotto U, Pelusi C. Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature. Rev Endocr Metab Disord. 2021;22(2):337–49.PubMedCrossRef
56.
Quandt Z, Young A, Anderson M. Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes. Clin Exp Immunol. 2020;200(2):131–40.PubMedPubMedCentralCrossRef
57.
Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018;4(2):173–82.PubMedCrossRef
58.
Byun DJ, Braunstein R, Flynn J, Zheng J, Lefkowitz RA, Kanbour S, et al. Immune checkpoint inhibitor–associated diabetes: a single-institution experience. Diabetes Care. 2020:dc200609.
59.
Girotra M, Hansen A, Farooki A, Byun DJ, Min L, Creelan BC, et al. The current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management. JNCI Cancer Spectr. 2018;2(3):pky021.PubMedPubMedCentralCrossRef
60.
Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes. 2018;67(8):1471–80.PubMedPubMedCentralCrossRef
61.
Yaura K, Sakurai K, Niitsuma S, Sato R, Takahashi K, Arihara Z. Fulminant type 1 diabetes mellitus developed about half a year after discontinuation of immune checkpoint inhibitor combination therapy with nivolumab and ipilimumab: a case report. Tohoku J Exp Med. 2021;254(4):253–6.PubMedCrossRef
62.
Bastin M, Allouchery M, Sassier M, Rouby F, Eftekhari P, Lebrun-Vignes B, et al. Characteristics of insulinopenic and non insulinopenic diabetes related to immune checkpoint inhibitors: a French pharmacovigilance study. Therapie. 2021.
63.
Hanafusa T, Imagawa A. Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners. Nat Clin Pract Endocrinol Metab. 2007;3(1):36–45 quiz 2p following 69.PubMedCrossRef
64.
Grimmelmann I, Momma M, Zimmer L, Hassel JC, Heinzerling L, Pföhler C, et al. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - a multicentre study of 90 patients from the German Dermatooncology Group. Eur J Cancer. 2021;149:1–10.PubMedCrossRef
65.
Zhang AL, Wang F, Chang LS, McDonnell ME, Min L. Coexistence of immune checkpoint inhibitor-induced autoimmune diabetes and pancreatitis. Front Endocrinol (Lausanne). 2021;12:620522.CrossRef
66.
Hansen E, Sahasrabudhe D, Sievert L. A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome. Cancer Immunol Immunother. 65. Germany2016. p. 765-767.
67.
Trinh B, Donath MY, Läubli H. Successful treatment of immune checkpoint inhibitor-induced diabetes with infliximab. Diabetes Care. 42. United States2019. p. e153-e4.
68.
Oyer DS, Shah A, Bettenhausen S. How to manage steroid diabetes in the patient with cancer. J Support Oncol. 2006;4(9):479–83.PubMed
69.
Tamez-Pérez HE, Quintanilla-Flores DL, Rodríguez-Gutiérrez R, González-González JG, Tamez-Peña AL. Steroid hyperglycemia: prevalence, early detection and therapeutic recommendations: a narrative review. World J Diabetes. 2015;6(8):1073–81.PubMedPubMedCentralCrossRef
70.
Jeong Y, Han HS, Lee HD, Yang J, Jeong J, Choi MK, et al. A pilot study evaluating steroid-induced diabetes after antiemetic dexamethasone therapy in chemotherapy-treated cancer patients. Cancer Res Treat. 2016;48(4):1429–37.PubMedPubMedCentralCrossRef
71.
72.
Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract. 2009;15(5):469–74.PubMedCrossRef
73.
Yata Y, Hosojima M, Kabasawa H, Ishikawa T, Kaseda R, Iino N, et al. The assessment of the efficacy of dipeptidyl peptidase-4 inhibitors in patients with glucocorticoid-induced diabetes by continuous glucose monitoring. Intern Med. 2017;56(19):2555–62.PubMedPubMedCentralCrossRef
74.
• Aberer F, Hochfellner DA, Sourij H, Mader JK. A practical guide for the management of steroid induced hyperglycaemia in the hospital. J Clin Med. 2021;10(10):2154. Practical guidelines for management of glucocorticoid-induced hyperglycemia in the hospital.PubMedPubMedCentralCrossRef
75.
Chowdhury TA, Jacob P. Challenges in the management of people with diabetes and cancer. Diabet Med. 2019;36(7):795–802.PubMedCrossRef
76.
Tatalovic M, Lehmann R, Cheetham M, Nowak A, Battegay E, Rampini SK. Management of hyperglycaemia in persons with non-insulin-dependent type 2 diabetes mellitus who are started on systemic glucocorticoid therapy: a systematic review. BMJ Open. 2019;9(5):e028914.PubMedPubMedCentralCrossRef
77.
Foukas LC, Claret M, Pearce W, Okkenhaug K, Meek S, Peskett E, et al. Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature. 2006;441(7091):366–70.PubMedCrossRef
78.
Goncalves MD, Hopkins BD, Cantley LC. Phosphatidylinositol 3-kinase, growth disorders, and cancer. N Engl J Med. 2018;379(21):2052–62.PubMedCrossRef
79.
Juric D, Rodon J, Tabernero J, Janku F, Burris HA, Schellens JHM, et al. Phosphatidylinositol 3-kinase α-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study. J Clin Oncol. 2018;36(13):1291–9.PubMedPubMedCentralCrossRef
80.
André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. N Engl J Med. 2019;380(20):1929–40.CrossRef
81.
Shields M, Mo Q, Armitage M, Sharpe SC, Costa RLB. A systematic review and meta-analysis of selected toxicity endpoints of alpelisib. Oncotarget. 2020;11(42).
82.
Aggarwal R, Grabowsky J, Strait N, Cockerill A, Munster P. Impact of patient ethnicity on the metabolic and immunologic effects of PI3K-mTOR pathway inhibition in patients with solid tumor malignancies. Cancer Chemother Pharmacol. 2014;74(2):359–65.PubMedPubMedCentralCrossRef
83.
Goldman JW, Mendenhall MA, Rettinger SR. Hyperglycemia associated with targeted oncologic treatment: mechanisms and management. Oncologist. 2016;21(11):1326–36.PubMedPubMedCentralCrossRef
84.
Khan KH, Wong M, Rihawi K, Bodla S, Morganstein D, Banerji U, et al. Hyperglycemia and phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) inhibitors in phase I trials: incidence, predictive factors, and management. Oncologist. 2016;21(7):855–60.PubMedPubMedCentralCrossRef
85.
•• Rugo HS, André F, Yamashita T, Cerda H, Toledano I, Stemmer SM, et al. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol. 2020;31(8):1001–10. Details evaluation and management of hyperglycemia in clinical trial of PI3K inhibitor alpelisib for breast cancer.
86.
Patnaik A, Appleman LJ, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, et al. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin’s lymphomas. Ann Oncol. 2016;27(10):1928–40.PubMedPubMedCentralCrossRef
87.
Busaidy NL, Farooki A, Dowlati A, Perentesis JP, Dancey JE, Doyle LA, et al. Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol. 2012;30(23):2919–28.PubMedPubMedCentralCrossRef
88.
Farah SJ, Masri N, Ghanem H, Azar M. Diabetic ketoacidosis associated with alpelisib treatment of metastatic breast cancer. AACE Clin Case Rep. 2020;6(6):e349–e51.PubMedPubMedCentralCrossRef
89.
• Carrillo M, Rodriguez RM, Walsh CL, McGarvey M. Alpelisib-induced diabetic ketoacidosis: a case report and review of literature. AACE Clin Case Rep. 2021;7(2):127–31. A case and narrative review of unusual presentations of hyperglycemia from PI3K inhibitors.PubMedCrossRef
90.
91.
92.
Novosyadlyy R, Lann DE, Vijayakumar A, Rowzee A, Lazzarino DA, Fierz Y, et al. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res. 2010;70(2):741–51.PubMedPubMedCentralCrossRef
Metadaten
Titel
Patient-Centered Diabetes Care of Cancer Patients
verfasst von
Anupam Kotwal
Yee-Ming M. Cheung
Grace Cromwell
Andjela Drincic
Houry Leblebjian
Zoe Quandt
Robert J. Rushakoff
Marie E. McDonnell
Publikationsdatum
01.12.2021
Verlag
Springer US
Erschienen in
Current Diabetes Reports / Ausgabe 12/2021
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-021-01435-y

Weitere Artikel der Ausgabe 12/2021

Current Diabetes Reports 12/2021 Zur Ausgabe

Microvascular Complications—Retinopathy (R Channa, Section Editor)

Pediatric Diabetic Retinopathy: Updates in Prevalence, Risk Factors, Screening, and Management

Other Forms of Diabetes and Its Complications (JJ Nolan and H Thabit, Section Editors)

Diagnostic and Treatment Considerations in Restless Legs Syndrome Complicated by Diabetic Neuropathy

Pediatric Type 2 and Monogenic Diabetes (O Pinhas-Hamiel, Section Editor)

Adolescent Immigration and Type-2 Diabetes

Other Forms of Diabetes and Its Complications (B Wojeck and H Yaggi, Section Editors)

Sleep Apnea and Cardiovascular Disease

Lifestyle Management to Reduce Diabetes/Cardiovascular Risk (B Conway and H Keenan, Section Editors)

Consumption of Non-nutritive Sweeteners and Risk for Type 2 Diabetes: What Do We Know, and Not?

Diabetes Epidemiology (HC Yeh, Section Editor)

Neighbourhood Walkability and Risk of Diabetes: Causal Relationship or Epidemiologic Association?

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 | Parkinson-Krankheit | Nachrichten

Viel Bewegung in der Parkinsonforschung

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise